Allopurinol: Clinical Trials

183 trials of Allopurinol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

132 completed, 19 unknown, 15 terminated, 10 recruiting. 65 Phase 2, 44 Phase 3, 39 Phase 4, 27 Phase 1, 16 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 265Completed 48, Terminated 7, Unknown 5, Recruiting 3, Withdrawn 2
Phase 344Completed 30, Recruiting 6, Unknown 5, Terminated 3
Phase 439Completed 27, Unknown 5, Terminated 4, Recruiting 2, Not yet recruiting 1
Phase 127Completed 22, Terminated 2, Withdrawn 2, Unknown 1
Not applicable16Completed 8, Unknown 4, Withdrawn 2, Active not recruiting 1, Terminated 1
Early Phase 14Completed 3, Withdrawn 1

Follow Allopurinol: new trials by email Literature Review of Allopurinol trials Research Report on Allopurinol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Allopurinol in Depression
Sertraline 50 MG, Allopurinol 300 MG - Depression
Phase 2 / Phase 3RecruitingTanta University702026-05-202026-08-18
Comparison of the Effect of Allopurinol Versus Febuxostat on Serum Uric Acid in Patients With Chronic Kidney Disease Associated With Hyperuricemia
Febuxostat, allopurinol - Hyperuricemia, Renal Insufficiency, Chronic
Not applicableActive not recruitingNishtar Medical University662026-05-132026-09-30
Drug-Drug Interaction Study of ABP-671 in Gout Patients
ABP-671 plus allopurinol - Gout Chronic, Gout
Phase 1CompletedAtom Therapeutics Co., Ltd222026-01-232026-11-02
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness
HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis
Phase 4Not yet recruitingHaiphong University of Medicine and Pharmacy2282026-01-202026-01-27
Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver
Allopurinol Tablet, Placebo - Cirrhoses, Liver, Decompensated Cirrhosis of Liver
Phase 4RecruitingBangladesh Medical University542025-09-102026-09-02
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Allopurinol, Dotinurad - Tophaceous Gout
Phase 3RecruitingCrystalys Therapeutics2502025-08-042026-11-12
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Allopurinol, Dotinurad - Gout
Phase 3RecruitingCrystalys Therapeutics5002025-08-012026-11-12
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
Allopurinol - Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Phase 2CompletedVA Office of Research and Development402024-09-302026-09-04
Extension Study of ABP-671 in Participants With Gout
ABP-671, Allopurinol - Gout
Phase 2 / Phase 3TerminatedAtom Therapeutics Co., Ltd432024-04-222025-07-16
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg - Gout
Phase 4RecruitingMassachusetts General Hospital6502024-02-222026-11-18
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia
Phase 1 / Phase 2CompletedUrica Therapeutics Inc.202023-10-042026-06-10
The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk
Allopurinol 200 mg, Optional intervention - Cardiovascular Diseases, Uric Acid
Phase 3RecruitingPoznan University of Medical Sciences11162023-09-012025-01-06
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
ABP-671, Allopurinol, Placebo - Gout
Phase 2 / Phase 3CompletedAtom Therapeutics Co., Ltd3002023-08-112025-12-22
ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS
Allopurinol - Diabetic Kidney Disease (DKD)
Not applicableCompletedNarowal Medical College802023-05-142025-09-17
Allo HSCT Using RIC and PTCy for Hematological Diseases
Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Phase 2RecruitingMasonic Cancer Center, University of Minnesota562023-05-012026-07-06
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
D-0120, Allopurinol - Gout
Phase 2CompletedInventisBio Co., Ltd802023-04-172026-07-09
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia
Phase 3CompletedLG Chem22022023-03-302025-07-22
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Mycophenolate Mofetil, Allopurinol, Irinotecan - Small-cell Lung Cancer, Small Cell Lung Carcinoma
Phase 1TerminatedWashington University School of Medicine172023-02-272024-12-05
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Pirtobrutinib, Obinutuzumab, Venetoclax - Leukemia
Phase 2RecruitingM.D. Anderson Cancer Center602022-12-202026-04-30
Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients
Trimetazidine 35 mg, Allopurinol 300 MG, Normal saline - AKI - Acute Kidney Injury
Phase 4UnknownBeni-Suef University1242022-09-192023-01-19

Showing 20 of 183. Sign in to see all of them.

Conditions studied

Gout (45)  ·  Hyperuricemia (35)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (11)  ·  Renal Insufficiency, Chronic (11)  ·  Cardiovascular Diseases (10)  ·  Leukemia (10)  ·  Leukemia, Myeloid, Acute (8)  ·  Lymphoma (8)  ·  Lymphoma, Non-Hodgkin (8)  ·  Burkitt Lymphoma (7)  ·  Heart Failure (7)  ·  Hypertension (7)  ·  Myelodysplastic Syndromes (7)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Lymphoma, Follicular (5)

Sponsors

Ardea Biosciences, Inc. (10)  ·  AstraZeneca (7)  ·  Masonic Cancer Center, University of Minnesota (6)  ·  Takeda (6)  ·  Tanta University (5)  ·  University of Dundee (5)  ·  Alliance for Clinical Trials in Oncology (4)  ·  Arthrosi Therapeutics (3)  ·  Atom Therapeutics Co., Ltd (3)  ·  Gilead Sciences (3)  ·  Instituto Nacional de Cardiologia Ignacio Chavez (3)  ·  M.D. Anderson Cancer Center (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)  ·  The University of Texas at Arlington (3)

Countries

United States (93)  ·  United Kingdom (13)  ·  Canada (11)  ·  Germany (11)  ·  Poland (11)  ·  Spain (11)  ·  Australia (8)  ·  Egypt (8)  ·  China (7)  ·  Italy (6)  ·  Mexico (6)  ·  Taiwan (6)  ·  Belgium (5)  ·  Brazil (5)  ·  Georgia (5)

Top investigators

N. Bhakta (3)  ·  Allan Struthers, MD FRCP (2)  ·  Chris Storgard, MD (2)  ·  Daniel I Feig, MD, PhD (2)  ·  Magdalena Madero, MD (2)  ·  AA Levine (1)  ·  Adrian Hernandez, MD (1)  ·  Ahmed A. Shokeir, MD (1)  ·  Alaattin Yildiz, Prof, MD (1)

Results publications

PMID 21849262, PMID 21353107, PMID 22052584, PMID 35835008, PMID 18600509, PMID 37832758, PMID 12421831, PMID 15698861, PMID 16339094, PMID 17241381, PMID 18349746, PMID 18681754, PMID 18728266, PMID 18975369, PMID 19286847, PMID 19564319, PMID 20029377, PMID 20370912, PMID 20674758, PMID 20952687, PMID 22132950, PMID 22316106, PMID 22361399, PMID 22420596, PMID 22436129, PMID 22483162, PMID 22795277, PMID 23006736, PMID 23098865, PMID 23395281, PMID 23683134, PMID 23740194, PMID 23929928, PMID 24352085, PMID 24428673, PMID 24530972, PMID 25512466, PMID 25986447, PMID 26013187, PMID 26190562, PMID 26216382, PMID 26277090, PMID 26724837, PMID 26742777, PMID 26989892, PMID 27564409, PMID 27821644, PMID 28739782, PMID 29527974, PMID 29531784

NIH funding

U10CA031946 (4), 2017 (3), 2014 (2), 2016 (2), K23DK064587 (2), 2018 (1), 2019 (1), I21RX004655 (1), K23DK088833 (1), K23HL071562 (1), P30CA016056 (1), P50AR060772 (1), R01DK103729 (1), R01HL061912 (1), R01HL079352 (1)